Compounds provided herein are novel substituted pyrazinones, pyridines and pyrimidines of Formula (I) and (II): ##STR00001## Such compounds are particularly useful as CRF receptor ligands, and hence, in the treatment of various neurologically-related disorders such as affective disorder, anxiety and depression.